Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
122
Views
14
CrossRef citations to date
0
Altmetric
Review

NSAIDs and gastrointestinal complications: new clinical challenges

Neena S Abraham Gastroenterology Section, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd. (152), Houston, TX 77030, USA. [email protected]
&
David Y Graham Health Services Research (Houston Center for Quality of Care Utilization Studies), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd. (152), Houston, TX 77030, USA
Pages 2681-2689 | Published online: 30 Nov 2005

Bibliography

  • SINGH G, ROSEN RD: NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol (1998) 51(Suppl.):8–16.
  • •A National Institute of Health-funded, prospective database study of arthritis patients that contributes much of our epidemiological understanding of the risks of NSAID gastrointestinal toxicity.
  • THOMAS J, STRAUS WL, BLOOM BS: Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am. J. GastroenteroL (2002) 97(9):2215–2219.
  • SCHEIMAN JM, FENDRICK AM: NSAIDs without a prescription: over-the-counter access, under-counted risks. Am. J. GastroenteroL (2002) 97(9):2159–2161.
  • GOLDSTEIN JL, LEFKOWITH J: Public misunderstanding of non-steroidal anti-inflammatory drug (NSAID)-mediated gastrointestinal (GI) toxicity: a serious potential health threat. Gastroenterology (1998) 114:A555 (Abstr.).
  • GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. (1991) 115(10):787–796.
  • MCCARTHY D: Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am. J. Med. (1998) 105(5A):35–95.
  • SMALLEY WE, RAY WA, DAUGHERTY JR, GRIFFIN MR: Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am. J. Epidemiol (1995) 141(6):539–545.
  • •Presents compelling epidemiological evidence of the vulnerability of the elderly with regard to NSAID-induced ulcers.
  • BOMBARDIER C, LAINE L, REICIN A et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in Patients with rheumatoid arthritis. VIGOR Study Group. N Engl. J. Med. (2000) 343(21):1520–1528.
  • OFMAN JJ, MACLEAN CH, STRAUS WL et al.: A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. Rheumatol (2002) 29(4):804–812.
  • WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl J. Med. (1999) 340(24):1888–1899.
  • SMALLEY WE, GRIFFIN MR, FOUGHT RL, RAY WA: Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J. Gen. Intern. Med. (1996) 11(8):461–469.
  • LAINE L, WOGEN J, YU H: Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology (2003) 125(2):389–395.
  • RAHME E, JOSEPH L, KONG SX, WATSON DJ, LELORIER J: Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. (2000) 43(4):917–924.
  • SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247–1255.
  • HERNANDEZ-DIAZ S, GARCIA-RODRIGUEZ LA: Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am. J. Med. (2001) 110(Suppl. 3A):205–275.
  • •A good overview of the epidemiology of NSAID toxicity.
  • TARONE RE, BLOT WJ, MCLAUGHLIN JK: Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am. J. Ther. (2004) 11(1):17–25.
  • ••An excellent synopsis of epidemiologicalrisks for NSAID toxicity.
  • GARCIA RODRIGUEZ LA, JICK H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 343(8900):769–772.
  • HENRY D, LIM LL, GARCIA RODRIGUEZ LA et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ (1996) 312(7046):1563–1566.
  • FRIES JF, WILLIAMS CA, BLOCH DA: The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis. Rheum. (1991) 34(11):1353–1360.
  • WEIDEMAN RA, KELLY KC, KAZI S et al.: Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology (2004) 127(5):1322–1328.
  • HUANG JQ, SRIDHAR S, HUNT RH: Gastrointestinal safety profile of nabumetone: a meta-analysis. Am. J. Med. (1999) 107(6A):55S–61S.
  • SCHOENFELD P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med. (1999) 107(6A):48S–54S.
  • HUNT RH, BARKUN AN, BARON D et al.: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can. J. Gastroenterol (2002) 16(4):231–240.
  • WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96(13):7563–7568.
  • ••Excellent comparative review of the COXselectivity of common NSAIDs.
  • CHAN FK, GRAHAM DY: Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment. Pharmacol Ther. (2004) 19(10):1051–1061.
  • ••Good review of current recommendationsfor gastroprotective agent use.
  • COOPER SA, WAGENBERG B, ESKOW R, ZISSU J: Double-blind evaluation of ibuprofen and aspirin in the treatment of periodontal pain. Pharmacology (1983) 27\(Suppl. 1):23–30.
  • LANAS A. SEKAR MC, HIRSCHOWITZ BI: Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology (1992) 103(3):862–869.
  • MAJERUS PW, STANFORD N: Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles. Br. J. Clin. Pharmacol. (1977) 4\(Suppl. 1):155–185.
  • GRAHAM DY: Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am. J. Gastroenterol (1996) 91(10):2080–2086.
  • JONES RA: Etodolac: clinical profile of an established selective cyclooxygenase-2 inhibitor. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RM (Eds). William Harvey Press, London (2001):482–497.
  • SILVERSTEIN FE, GRAHAM DY, SENIOR JR RM et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123(4):241–249.
  • •Best evidence for the use of a gastroprotective agent for the reduction of NSAID-related gastrointestinal complications.
  • GRAHAM DY, WHITE RH, MORELAND LW et al.: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann. Intern. Med. (1993) 119(4):257–262.
  • CHAN FK, CHUNG SC, SUEN BY et al: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl. J. Med. (2001) 344(13):967–973.
  • GRAHAM DY, AGRAWAL NM, CAMPBELL DR et al.: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch. Intern. Med. (2002) 162(2):169–175.
  • YEOMANS ND, TULASSAY Z, JUHASZ L et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl. J. Med. (1998) 338(11):719–726.
  • GRAHAM DY: Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter (2002) 7(1):1–8.
  • ••Eradication of H. pylori is likely to beresponsible for the reduction in NSAID-ulcers noted with concomitant proton pump inhibitor use.
  • GRAHAM DY: NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl. J. Med. (2002) 347(26):2162–2164.
  • LANZA FL: A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol (1998) 93(11):2037–2046.
  • Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. (2000) 43(9):1905–1915.
  • SCHNITZER TJ: Update of ACR guidelines for osteoarthritis: role of the coxibs. J. Pain Symptom Manage. (2002) 23(4 Suppl.):524–530.
  • AGRAWAL NM, CALDWELL J, KIVITZ AJ et al.: Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin. Ther. (1999) 21(4):659–674.
  • BOCANEGRA TS, WEAVER AL, TINDALL EA et al.: Diclofenac/ misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. Rheumatol (1998) 25(8):1602–1611.
  • LISSE JR, PERLMAN M, JOHANSSON G et al.: Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann. Intern. Med. (2003) 139(7):539–546.
  • PEURA DA, LANZA FL, GOSTOUT CJ, FOUTCH PG: The American College of Gastroenterology Bleeding Registry: preliminary findings. Am. J. Gastroenterol (1997) 92(6):924–928.
  • COX ER, FRISSE M, BEHM A, FAIRMAN KA: Over-the-counter pain reliever and aspirin use with a sample of long-term cyclooxygenase 2 users. Arch. Intern. Med. (2004) 164:1243–1245.
  • LEWIS JD, BILKER WB, BRENSINGER C, FARRAR JT, STROM BL: Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am. J. Gastroenterol (2002) 97(10):2540–2549. ••Clarifies the epidemiological role of over-the-counter NSAIDs on hospitalisation and mortality rates.
  • SCHEIMAN JM, CRYER B, KIMMEY MB, ROTHSTEIN RI, RIFF DS, WOLFE MM: A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin. Gastroenterol Hipatol. (2004) 2(4):290–295.
  • HUANG JQ, SRIDHAR S, HUNT RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 359(9300):14–22.
  • •Highlights the synergistic risk of Helicobacter pylori infection and NSAID use.
  • MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2–2000 Consensus Report. Aliment. Pharmacol Ther. (2002) 16(2):167–180.
  • •Consensus conference results regarding diagnosis, therapy and the role of co-infection among NSAID users.
  • GRAHAM DY, LEW GM, KLEIN PD et al.: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann. Intern. Med. (1992) 116(9):705–708.
  • CHAN FK, SUNG JJ, CHUNG SC et al.:Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (1997) 350(9083):975–979.
  • GRAHAM DY, HEPPS KS, RAMIREZ FC, LEW GM, SAEED ZA: Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand. J. Gastroenterol (1993) 28(11):939–942.
  • DERRY S, LOKE YK: Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) 321(7270):1183–1187.
  • WEIL J, COLIN-JONES D, LANGMAN M et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 310(6983):827–830.
  • SORENSEN HT, MELLEMKJAER L, BLOT WJ et al.: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol (2000) 95(9):2218–2224.
  • WILCOX CM, SHALEK KA, COTSONIS G: Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch. Intern. Med. (1994) 154(1):42–46.
  • LAUER MS: Clinical practice. Aspirin for primary prevention of coronary events. N Engl. J. Med. (2002) 346(19):1468–1474.
  • RAY WA, STEIN CM, HALL K, DAUGHERTY JR, GRIFFIN MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 359(9301):118–123.
  • GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. (2001) 3(2):98–101.
  • LAINE L: Gastrointestinal effects of NSAIDs and coxibs. J. Pain Symptom Manage. (2003) 25(2 Suppl.):532–540.
  • KIMMEL SE, BERLIN JA, REILLY M et al.: The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol (2004) 43(6):985–990.
  • RAHME E, BARDOU M, DASGUPTA K, BARKUN A: Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Gastroenterology (2004) 126(4 Suppl. 2):9 (Abstr.).
  • FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. (2001) 345(0:433–442.
  • SINGH D: Merck withdraws arthritis drug worldwide. BMJ (2004) 329(7470):816.
  • OTT E, NUSSMEIER NA, DUKE PC et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg (2003) 125(6):1481–1492.
  • SOLOMON SD, MCMURRAY JJV, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl. J. Med. (2005) 352(11):1071–1080.
  • KIMMEL SE, BERLIN JA, REILLY M et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. (2005) 142(3):157–164.
  • TALLEY NJ, EVANS JM, FLEMING KC, HARMSEN WS, ZINSMEISTER AR, MELTON LJ III: Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig. Dis. Sci. (1995) 40(6):1345–1350.
  • GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am. J. Epidemiol. (2004) 159(1):23–31.
  • HANSEN JM, HALLAS J, LAURITSEN JM, BYTZER P: Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand. Gastroenterol (1996) 31(2):126–130.
  • GRIFFIN MR, RAY WA, SCHAFFNER W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med. (1988) 109(5):359–363.
  • GRIFFIN MR, PIPER JM, DAUGHERTY JR, SNOWDEN M, RAY WA: Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern. Med. (1991) 114(4):257–263.
  • LAINE L, BOMBARDIER C, HAWKEY CJ et al.: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology (2002) 123(4) :1006–1012.
  • SHORR RI, RAY WA, DAUGHERTY JR, GRIFFIN MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med. (1993) 153(14):1665–1670. Websites

Websites

  • http://www.fda.gov/cder/drug/analgesics/ healthHints.htm Use caution with pain relievers (2004).
  • http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3677b1_03_med.pdf FDA Advisory Committee. Briefing information: NDA20-998/s009 Celebrex® (celecoxib) (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.